ABSTRACT: In this paper, we describe the discovery and optimization of a new chemotype of isoform selective PI3Kγ inhibitors. Starting from an HTS hit, potency and physicochemical properties could be improved to give compounds such as 15, which is a potent and remarkably selective PI3Kγ inhibitor with ADME properties suitable for oral administration. Compound 15 was advanced into in vivo studies showing dose-dependent inhibition of LPS-induced airway neutrophilia in rats when administered orally.
■ INTRODUCTION
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases whose primary function is to catalyze phosphorylation of the 3-position of the inositol ring of membrane phosphoinositides. This initiates a complex downstream signaling network that regulates cell growth, survival, migration, and proliferation. The PI3K family is clustered into three different classes (classes I, II, and III) based on structural features and substrate preference. Class I consists of four isoforms (α, β, γ, and δ). It is by far the most extensively studied of the PI3K classes and has been an attractive target for the pharmaceutical industry over the past decade. The PI3Kγ isoform is primarily found in leukocytes and is a key regulator of cellular migration.
1,2 A PI3Kγ inhibitor could thus potentially be used to treat a variety of diseases in which influx of inflammatory effector cells plays a key role in pathology, including diseases within the areas of respiratory and inflammation, metabolic disorders, and cancer. 3−5 Unfortunately, highly selective PI3Kγ inhibitors are rare as it has been difficult to identify truly isoenzyme selective compounds due to the high sequence homology between the PI3K isoforms. From a safety perspective, high isoform selectivity is essential as PI3Kα has been shown to affect glucose and insulin signaling. 6 It has also been shown that PI3Kγ knockout mice are viable and fertile while genetic inactivation of PI3Kα or -β results in embryonic lethality. 7, 8 Recently compounds with high γ isoform selectivity have been reported, including IPI-549 which is currently in clinical trials in immuno-oncology applications. 9−11 We now report our discovery of a series of highly selective PI3Kγ inhibitors. This series, which was identified in a HTS, contains an isoindolinone core that extends deep into the ATPbinding pocket and utilizes a selectivity switch that has not been previously described for PI3K inhibitors.
■ RESULTS AND DISCUSSION
Our efforts to discover selective PI3Kγ inhibitors with suitable ADME properties for oral dosing started with a full HTS of our corporate screening collection using a biochemical enzyme inhibition assay for PI3Kγ. This was followed by a counterscreen for PI3Kα in order to identify series with some inherent PI3Kγ selectivity. One hit series contained an isoindolinone core ( Figure 1 ). Compound 1 was one of the most potent in this cluster and exhibited high selectivity toward PI3Kα. It was profiled in a PI3Kγ target engagement cell assay measuring phosphorylation of AKT but was inactive at 1 μM.
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The attractive selectivity profile meant that this series was still deemed to be of interest. It was not immediately apparent what binding mode the compounds might have in the PI3Kγ enzyme, and we made repeated efforts to crystallize compounds from this series with a PI3Kγ construct to guide further design but without success. This was surprising since PI3Kγ has been shown to be very amenable to crystallization and has often been used as a surrogate for the other class 1 PI3Ks; 13 at AstraZeneca our in-house database contains more than 80 PI3Kγ structures. We screened near neighbors of 1 to build a picture of the SAR. Compound 2, a methylated matched-pair analogue of 1, lost significant PI3Kγ activity (Figure 1 ). This prompted us to hypothesize that the acetamido-substituted isoxazole might interact with the hinge region of the kinase. Even though isoxazole is not a common hinge-binding motif, it does contain a hydrogen bond donor/acceptor pair typical for kinase inhibitors. The dependence of activity on the donor NH suggested this could be a good place to start exploring SAR.
A set of amino heterocycles that are typical kinase hingebinding motifs were therefore introduced to replace the isoxazole (Table 1) . Encouragingly, several of these such as aminopyrimidine 3 and pyrrolopyrazine 5 were potent inhibitors of PI3Kγ, supporting the hypothesis that this part of the molecule was interacting with the hinge. This was further strengthened with data for compounds 6−10 which all carried hinge-binding motifs that had been used in previously reported PI3Kγ inhibitors. 6, 14, 15 The introduction of an aminothiazole heterocycle in 7−10 gave a marked increase in enzyme potency, and to our delight this was also reflected in the data from the cell assay showing pIC 50 of 7−8 ( Table 1) . These results clearly supported the hypothesis that this part of the molecule was binding to the hinge region, but we were still unable to crystallize these more potent compounds in our PI3Kγ construct. Compounds 3−10 all showed very good selectivity toward the other class I isoforms. Compound 9, however, was a moderately potent inhibitor of PI3Kδ, and we therefore investigated crystallization in a PI3Kδ construct. Rewardingly, this was successful, and crystals of 9 in mouse PI3Kδ could be obtained ( Figure 2 ). The structure confirms that the aminothiazole heterocycle is interacting with the hinge residues as bidentate hydrogen bonds to Val828 are observed. The isoindolinone core forms hydrophobic interactions with Ile825 and the carbonyl of the lactam hydrogen-bonds with the catalytic Lys779. All these interactions are made with residues that are conserved between all four isoforms and do not give any clue to the high isoform selectivity observed in this series. However, one feature that is unique in this series is the N-alkyl tail, which is oriented perpendicular to the isoindolinone core, positioning the cyclopropyl ring close to Met788 and the methyl close to Asp787, both residues that form part of the kα3-helix (the equivalent to αC-helix in protein kinases). This observation prompted further investigation of the N-alkyl substituent, and a set of analogues was prepared. However, out of the 80 compounds prepared in this set no compound had increased potency compared to the original methylcyclopropyl moiety that originated from the HTS hit (data not shown). The stereochemistry did not have a large impact on selectivity or potency as the (R)-stereoisomer 10 had similar potency in the biochemical assay to the (S)-stereoisomer 8 but was slightly less potent in the cell assay (Table 1 ). More interesting results were obtained when removing the alkyl group from the nitrogen altogether giving compound 11 ( Table 2) .
Comparison of the matched-pair analogues 9 and 11 showed a dramatic 2 log drop in PI3Kγ potency, while PI3Kα potency increased by 1.6 log. Interestingly, PI3Kδ potency was hardly affected and PI3Kβ potency increased but less dramatically than α. The remarkable PI3Kγ selectivity thus seems to originate from the N-alkyl tail extending deep into the ATP-binding pocket and pushing on the kα3-helix. Comparison of the obtained structure with PI3Kγ-structures of reported selective inhibitors shows that this is a unique feature of this series as none of the reported inhibitors extend as far into the ATPbinding pocket ( Figure S1 , Supporting Information).
It is important to remember that the crystal structure of 9 is in murine PI3Kδ and thus may not reveal all structural details relevant to understanding the high PI3Kγ selectivity. Compound 9 was profiled in a panel of 132 kinases at 1 μM (Thermo Fisher). Approximately 100% inhibition was observed for PI3Kγ and also for DRAK1, while greater than 50% inhibition was observed for CLK4 and PI3Kδ (Table S1 , Supporting Information). The pIC 50 values of 9 against DRAK1, and CLK4 were determined and show that even though 9 has a good kinase selectivity profile it is also a potent inhibitor of DRAK1 and CLK4 with pIC 50 values of 8.0 and 6.9, respectively. The most potent compounds 8 and 9 did not have a suitable profile for oral administration as they had poor solubility, high in vitro clearance and were very lipophilic. To improve ADME properties, design was focused on reducing lipophilicity. It has been shown that sulfonamides, 6 reversed sulfonamides, 16 and sulfones 17 can be introduced in the ribose pocket of PI3Ks; overlay of the crystal structure of 9 with the public structure of PIK-93 (PDB code 2CHZ), 6 suggested that it could be possible to target the ribose pocket from the isoindolinone core by substitution on the 7-position ( Figure 3 ). This was judged to be a good position to introduce more polar functionalities to decrease lipophilicity. Sulfonamides 12−14, sulfones 15 and 16, and reversed sulfonamides 17 and 18 extending from the 7-position of the isoindolinone core were prepared. The majority of these compounds had maintained or increased PI3Kγ potency while at the same time having a lower log D (Table 3 ). The most potent compounds in the enzymatic and cellular assay were N-methylsulfonamide 13, methyl sulfone 15, and reversed methylsulfonamides 17 and 18. Compound 18, however, exhibited high intrinsic clearance in rat hepatocytes. Compounds 13, 15, and 17 were selected for further profiling. All the shortlisted compounds, 13, 15, and 17, showed excellent isoform selectivity in the biochemical assays, and this profile was also confirmed in mechanism-based cellular assays measuring phosphorylation of AKT. The compounds showed high activity in the PI3Kγ target engagement cell assay and >100-fold selectivity in a human Jeko-1B cell line that assesses PI3Kδ activity (Table 4 ). The compounds were inactive in two other cell assays: a human MDA MB-468 cell line and a human BT4 cell line that assess activity of PI3Kα and PI3Kβ, respectively. Compound 15 had considerably better kinetic solubility than 13 and 17 ( Table 3) . The difference was less pronounced when thermodynamic solubility at pH 6.5 was measured, but 15 was still the most soluble ( Table 4) . The compounds had a clear margin against inhibition of the hERG channel and also for general cytotoxicity assessed in THP1 cells and HepG2 cells. In vitro PK data of the three compounds showed that 15 consistently had the lowest intrinsic clearance and highest free fraction across three species (human, rat, and dog). In vivo, 17 showed low clearance in rat and had the longest half-life of the shortlisted compounds in this species.
Also in dog, 17 had a lower clearance than predicted from in vitro data, but in this species in vivo clearance was the highest among the three compounds. In addition, bioavailability of 17 in dog was only 1.6%. Compound 15 on the other hand had good bioavailability and low clearance in both species which was consistent with in vitro data. On the basis of these data, 15 was identified as the compound with the best profile for oral administration and was chosen for further profiling. Kinase selectivity profiling of 15 at 1 μM in a panel of 395 kinases (Thermo Fisher) including protein and lipid kinases showed excellent kinase selectivity (Table S2 , Supporting Information), and no activity could be detected for the previously observed off-targets DRAK1 and CLK4.
Except for PI3Kγ (95%) and -δ (66%) the only kinases that showed greater than 50% inhibition at 1 μM were the class II PI3Ks: PI3KC2β (84%) and PI3KC2γ (71%). Thus, to get a more complete view of the selectivity toward class II and class III PI3Ks, pIC 50 values of 15 against all class II and class III PI3Ks were determined (Table 5 ). These data showed that 15 inhibits the class II PI3K PI3KC2β with a pIC 50 of 7.5 as compared to a pIC 50 > 9.2 for PI3Kγ in a comparable biochemical assay. Relatively little is known about the role of class II PI3Ks, 18 and no notable activity of 15 was recorded for the other class II and class III PI3Ks.
Compound 15 was also screened in a wide ligand profile screen (CEREP), covering 89 distinct molecular targets (Table  S4 , Supporting Information). Compound 15 showed good selectivity margins, with only one target, P2Y 1 , with a K i below 1 μM. Follow-up screening showed no activity (<100 μM) of 15 as agonist or antagonist in whole cell P2Y 1 assays. On the basis of the encouraging pharmacokinetic and safety/selectivity profile of 15, we decided to progress into a rat LPS-induced acute inflammation model, measuring airway neutrophilia. Compound 15 was dosed 2 h prior to challenge and inhibited neutrophil migration with a dose-response over doses of 0.1, 0.5, and 2.5 mg/kg (Figure 4) . These data strongly suggest that oral administration of 15 inhibits PI3Kγ function in vivo.
Compound 15 was prepared in four steps starting from a methylester derivative that was reacted with (S)-1-cyclopropylethanamine to give isoindolinone 19 (Scheme 1). The aminothiazole was introduced by a Pd-catalyzed coupling of isoindolinone 19 with N-(4-methylthiazol-2-yl)acetamide. This was followed by an S N Ar reaction with sodium methanthiolate to give the intermediate sulfide which could be oxidized to the desired sulfone 15 by using m-CPBA.
■ CONCLUSION
A series of highly isoform-selective PI3Kγ inhibitors have been developed starting from a high quality HTS hit. This series, which contains an alkyl-substituted isoindolinone core, exhibits remarkable isoform selectivity which originates from the Nalkyl tail extending deep into the ATP-binding pocket. The initial hit was efficiently progressed by use of structure based design to more advanced compounds, e.g., 15. This compound combines high biochemical and cellular potency with excellent isoform selectivity and has an attractive pharmacokinetic and in vitro safety profile. Oral administration of 15 resulted in a dosedependent inhibition of LPS-induced airway neutrophilia in rats.
■ EXPERIMENTAL SECTION
All compounds were purified to ≥95% purity (HPLC). Further synthetic details and full descriptions of biological methods are contained in the Supporting Information. (15) . Sodium methanethiolate (5.0 g, 71 mmol) was added to 8 in DMF (80 mL). The resulting mixture was heated at 110°C for 2 h. The solvent was removed under reduced pressure, and the reaction mixture was poured into water. The resulting precipitate was collected by filtration, washed with water (200 mL) and EtOAc (50 mL), and dried under vacuum to afford the intermediate sulfide (4.10 g, 72%), which was used in the next step (below) without further purification.
m-CPBA (3.3 g, 19.3 mmol) was added to the sulfide prepared above (3.1 g, 7.7 mmol) in DCM (120 mL). The resulting mixture was stirred at 0°C for 1 h, then warmed to rt and stirred for 1 h. The reaction mixture was quenched with saturated NaHCO 3 (200 mL) and extracted with DCM. The organic layer was dried over Na 2 SO 4 , filtered, and concentrated. The crude product was purified by preparative HPLC to afford the title compound 15 (1.2 g, 36%) as a white solid. Figure 4 . Effect of compound 15 on LPS-induced neutrophil migration in rats. LPS challenged Wistar females were dosed po with 15 2 h prior to challenge. 4 h after challenge the animals were sacrificed. Lung fluid was collected by lavage, and differential cell count was performed using a SYSMEX XT-1800i. Neutrophil migration was significantly inhibited in a dose-dependent manner with 15. n = 8 in all groups (n = 10 for vehicle group). Statistical significance is indicated as follows above the columns: ( * ) p < 0.001; ( * * * ) p < 0.05. 5-Bromo-7-chloro-2-[(1S)-1-cyclopropylethyl]-2,3-dihydro-1H-isoindol-1-one (19). (S)-1-Cyclopropylethanamine (2.4 mL, 23 mmol) was added to a flask containing methyl 4-bromo-2-(bromomethyl)-6-chlorobenzoate (7.8 g, 23 mmol) in acetonitrile (80 mL). Boric acid (1.4 g, 23 mmol) was added, followed by portionwise addition of K 2 CO 3 (6.3 g, 46 mmol) over 2 min. The mixture was allowed to stir at rt overnight. The reaction mixture was filtered and washed with acetonitrile. The combined acetonitrile filtrates were concentrated and the residue was chromatographed (silica gel; 5−30% of EtOAc in heptane) to afford the title compound ■ ASSOCIATED CONTENT
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